Compare Lockheed Martin Corporation (LMT) vs Pfizer Inc (PFE) Price & Performance

Lockheed Martin (LMT) trades at $587.95, up 0.9% with bullish technical signals and strong institutional support. The company reported mixed Q2 2026 earnings with a beat on EPS ($7.94 vs. $7.22 expected) but maintains a record $230B backlog. Valuation metrics show a P/E of 21.68 and ROE of 89.16%, though recent quarters saw earnings misses. Technical indicators suggest bullish momentum with key resistance at $592.

Outlook remains positive driven by defense contract wins and production expansion, but risks include execution on massive backlog and debt levels. Analyst consensus is bullish with $608 price target representing 3.4% upside. The stock offers stability through dividends ($3.45 quarterly) amid geopolitical demand for defense systems.

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.